Compare LEDS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | VOR |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 207.1M |
| IPO Year | 2010 | 2021 |
| Metric | LEDS | VOR |
|---|---|---|
| Price | $1.96 | $12.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 24.5K | ★ 3.0M |
| Earning Date | 01-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,009,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.21 | $2.62 |
| 52 Week High | $3.37 | $65.80 |
| Indicator | LEDS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 50.52 |
| Support Level | $1.80 | $7.91 |
| Resistance Level | $2.00 | $12.82 |
| Average True Range (ATR) | 0.17 | 1.18 |
| MACD | -0.01 | 1.13 |
| Stochastic Oscillator | 13.93 | 72.11 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.